Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sigilon Therapeutics
Biotech
Lilly’s yes-no-yes journey to acquiring Sigilon
Sigilon really wanted to be bought by Eli Lilly. That much is clear in SEC documents filed Thursday that provide a peek behind the scenes of the deal.
Annalee Armstrong
Jul 13, 2023 11:20am
Lilly buys diabetes cell therapy partner Sigilon for $35M
Jun 29, 2023 8:00am
FDA puts Sigilon's hemophilia cell therapy trial on hold
Jul 9, 2021 11:07am
Sigilon picks up $80M to test hemophilia cell therapy in humans
Mar 17, 2020 7:00am